Literature DB >> 30672842

Outcomes of Primary Lymph Node Staging of Intermediate and High Risk Prostate Cancer with 68Ga-PSMA Positron Emission Tomography/Computerized Tomography Compared to Histological Correlation of Pelvic Lymph Node Pathology.

John W Yaxley1,2,3, Sheliyan Raveenthiran2, François-Xavier Nouhaud2,4, Hemamali Samartunga5,3, Anna J Yaxley6, Geoff Coughlin1,2, Brett Delahunt7, Lars Egevad8, Louise McEwan9, David Wong9.   

Abstract

PURPOSE: The majority of men who undergo pelvic lymph node dissection at radical prostatectomy have benign lymph node histology. The aim of this study was to assess the predictive value of preoperative 68Ga-PSMA (prostate specific membrane antigen) positron emission tomography/computerized tomography to predict histological metastasis on pelvic lymph node dissection performed during radical prostatectomy.
MATERIALS AND METHODS: We retrospectively reviewed the sensitivity, specificity, and positive and negative predictive values of preoperative staging 68Ga-PSMA positron emission tomography/computerized tomography to identify histological lymph node metastasis in 208 consecutive men who subsequently proceeded with pelvic lymph node dissection at radical prostatectomy.
RESULTS: Median prostate specific antigen was 7.6 μg/l, the lymph node count was 13 and Gleason score was 4 + 5. On a per patient basis only 21 of the 55 men with metastasis on histological examination were identified on 68Ga-PSMA positron emission tomography/computerized tomography for 38.2% sensitivity. Of the 143 men with no lymph node metastasis on 68Ga-PSMA imaging 34 had metastasis on histology for 80.8% negative predictive value. Specificity was 93.5% and positive predictive value was 67.7%. For the 172 histologically identified malignant lymph node metastases the sensitivity per node was 24.4% and specificity was 99.5%.
CONCLUSIONS: If negative 68Ga-PSMA positron emission tomography/computerized tomography is used as the basis of not performing pelvic lymph node dissection, 80% of men would avoid unnecessary pelvic lymph node dissection. However, 68Ga-PSMA positron emission tomography/computerized tomography has poor sensitivity per node to detect all histologically positive lymph node metastases. Thus, pelvic lymph node dissection remains the gold standard to stage pelvic lymph nodes despite its known limitations and complications.

Entities:  

Keywords:  emission-computed; lymph node excision; neoplasm staging; positron-emission tomography; prostatic neoplasms; tomography

Mesh:

Substances:

Year:  2019        PMID: 30672842     DOI: 10.1097/JU.0000000000000053

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  14 in total

1.  A comparison between 68Ga-labeled prostate-specific membrane antigen-PET/CT and multiparametric MRI for excluding regional metastases prior to radical prostatectomy.

Authors:  Michael Frumer; Nadav Milk; Gal Rinott Mizrahi; Sergiu Bistritzky; Itay Sternberg; Ilan Leibovitch; Yoram Dekel; Gilad E Amiel; Amnon Zisman; Jack Baniel; Miki Haifler; Jonathan Gal; Azik Hoffman; Itay Sagy; Barak Rosenzweig; Rennen Haramaty; Shay Golan
Journal:  Abdom Radiol (NY)       Date:  2020-07-15

2.  68Ga-PSMA PET/CT compared with MRI/CT and diffusion-weighted MRI for primary lymph node staging prior to definitive radiotherapy in prostate cancer: a prospective diagnostic test accuracy study.

Authors:  Lars J Petersen; Julie B Nielsen; Niels C Langkilde; Astrid Petersen; Ali Afshar-Oromieh; Nandita M De Souza; Katja De Paepe; Rune V Fisker; Dennis T Arp; Jesper Carl; Uwe Haberkorn; Helle D Zacho
Journal:  World J Urol       Date:  2019-06-12       Impact factor: 4.226

3.  Good clinical practice recommendations for the use of PET/CT in oncology.

Authors:  Pierre-Yves Salaün; Ronan Abgral; Olivier Malard; Solène Querellou-Lefranc; Gilles Quere; Myriam Wartski; Romain Coriat; Elif Hindie; David Taieb; Antoine Tabarin; Antoine Girard; Jean-François Grellier; Isabelle Brenot-Rossi; David Groheux; Caroline Rousseau; Désirée Deandreis; Jean-Louis Alberini; Caroline Bodet-Milin; Emmanuel Itti; Olivier Casasnovas; Françoise Kraeber-Bodere; Philippe Moreau; Arnaud Philip; Corinne Balleyguier; Alain Luciani; Florent Cachin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-10-21       Impact factor: 9.236

4.  Preoperative PSMA-PET/CT as a predictor of biochemical persistence and early recurrence following radical prostatectomy with lymph node dissection.

Authors:  D J H Baas; M Schilham; R Hermsen; J M S de Baaij; H J E J Vrijhof; R J Hoekstra; J P M Sedelaar; H V N Küsters-Vandevelde; M Gotthardt; C H W Wijers; J P van Basten; D M Somford
Journal:  Prostate Cancer Prostatic Dis       Date:  2021-09-01       Impact factor: 5.554

Review 5.  Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature.

Authors:  Henk B Luiting; Pim J van Leeuwen; Martijn B Busstra; Tessa Brabander; Henk G van der Poel; Maarten L Donswijk; André N Vis; Louise Emmett; Phillip D Stricker; Monique J Roobol
Journal:  BJU Int       Date:  2019-11-29       Impact factor: 5.588

Review 6.  18F-Facbc in Prostate Cancer: A Systematic Review and Meta-Analysis.

Authors:  Riccardo Laudicella; Domenico Albano; Pierpaolo Alongi; Giovanni Argiroffi; Matteo Bauckneht; Sergio Baldari; Francesco Bertagna; Michele Boero; Giuseppe De Vincentis; Angelo Del Sole; Giuseppe Rubini; Lorenzo Fantechi; Viviana Frantellizzi; Gloria Ganduscio; Priscilla Guglielmo; Anna Giulia Nappi; Laura Evangelista
Journal:  Cancers (Basel)       Date:  2019-09-11       Impact factor: 6.639

7.  A novel robust nomogram based on peripheral monocyte counts for predicting lymph node metastasis of prostate cancer.

Authors:  Jia-Wei Zhou; Yun-Hua Mao; Yang Liu; Hai-Tao Liang; Chandni Chandur Samtani; Yue-Wu Fu; Yun-Lin Ye; Gang Xiao; Zi-Ke Qin; Cun-Dong Liu; Jian-Kun Yang; Qi-Zhao Zhou; Wen-Bin Guo; Kang-Yi Xue; Shan-Chao Zhao; Ming-Kun Chen
Journal:  Asian J Androl       Date:  2021 Jul-Aug       Impact factor: 3.285

8.  11C-Choline PET/CT in Recurrent Prostate Cancer: Retrospective Analysis in a Large U.S. Patient Series.

Authors:  Laure Michaud; Karim A Touijer; Audrey Mauguen; Michael J Zelefsky; Michael J Morris; Serge K Lyashschenko; Jeremy C Durack; John L Humm; Wolfgang A Weber; Heiko Schöder
Journal:  J Nucl Med       Date:  2019-12-20       Impact factor: 11.082

9.  PSMA PET for primary lymph node staging of intermediate and high-risk prostate cancer: an expedited systematic review.

Authors:  Lars J Petersen; Helle D Zacho
Journal:  Cancer Imaging       Date:  2020-01-23       Impact factor: 3.909

10.  The Role of Ga-68-PSMA PET/CT in the Initial Staging of Prostate Cancer - A Single Center 4 Year Experience.

Authors:  João P Lima; João Carvalho; Vasco Quaresma; Edgar Tavares-da-Silva; Rodolfo Silva; Paulo Azinhais; Gracinda Costa; Arnaldo Figueiredo
Journal:  Res Rep Urol       Date:  2021-07-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.